Non-Small-Cell Lung Carcinoma (NSCLC) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: NF1F22711EB7EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Non-Small-Cell Lung Carcinoma (NSCLC) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Non-Small-Cell Lung Carcinoma (NSCLC) Understanding

The DelveInsight Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology report gives a thorough understanding of the Non-Small-Cell Lung Carcinoma (NSCLC) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Non-Small-Cell Lung Carcinoma (NSCLC) in the US, Europe, and Japan. The report covers the detailed information of the Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology scenario in seven major countries (US, EU5, and Japan).

Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Perspective by DelveInsight

The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Non-Small-Cell Lung Carcinoma (NSCLC) Detailed Epidemiology Segmentation

The Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology covered in the report provides historical as well as forecasted Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Non-Small-Cell Lung Carcinoma (NSCLC) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Non-Small-Cell Lung Carcinoma (NSCLC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Report and Model provide an overview of the global trends of Non-Small-Cell Lung Carcinoma (NSCLC) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Non-Small-Cell Lung Carcinoma (NSCLC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Non-Small-Cell Lung Carcinoma (NSCLC)
• The report provides the segmentation of the Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology

Report Highlights

• 11-year Forecast of Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Non-Small-Cell Lung Carcinoma (NSCLC)
• Cases of Non-Small-Cell Lung Carcinoma (NSCLC) by Mutation Types
• Non-Small-Cell Lung Carcinoma (NSCLC) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-Small-Cell Lung Carcinoma (NSCLC)?
• What are the key findings pertaining to the Non-Small-Cell Lung Carcinoma (NSCLC) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Non-Small-Cell Lung Carcinoma (NSCLC) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Non-Small-Cell Lung Carcinoma (NSCLC)?
• What are the currently available treatments of Non-Small-Cell Lung Carcinoma (NSCLC)?

Reasons to buy

The Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Non-Small-Cell Lung Carcinoma (NSCLC) market
• Quantify patient populations in the global Non-Small-Cell Lung Carcinoma (NSCLC) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Small-Cell Lung Carcinoma (NSCLC) therapeutics in each of the markets covered
• Understand the magnitude of Non-Small-Cell Lung Carcinoma (NSCLC) population by its epidemiology
• The Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF NON-SMALL-CELL LUNG CARCINOMA (NSCLC)

3. NON-SMALL-CELL LUNG CARCINOMA (NSCLC): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Non-Small-Cell Lung Carcinoma (NSCLC) Treatment and Management
6.2. Non-Small-Cell Lung Carcinoma (NSCLC) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in 7MM (2019-2032)
Table 2: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United States (2019-2032)
Table 4: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Germany (2019-2032)
Table 6: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in France (2019-2032)
Table 8: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Italy (2019-2032)
Table 10: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Spain (2019-2032)
Table 12: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United Kingdom (2019-2032)
Table 14: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Japan (2019-2032)
Table 16: Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in 7MM (2019-2032)
Figure 2 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United States (2019-2032)
Figure 4 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Germany (2019-2032)
Figure 6 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in France (2019-2032)
Figure 8 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Italy (2019-2032)
Figure 10 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Spain (2019-2032)
Figure 12 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Non-Small-Cell Lung Carcinoma (NSCLC) Epidemiology in Japan (2019-2032)
Figure 16 Non-Small-Cell Lung Carcinoma (NSCLC) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report